Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 1;115(42):10648–10653. doi: 10.1073/pnas.1806908115

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published under the PNAS license.

PMC Copyright notice

Fig. 5. — Immune cells are cleared more rapidly following PA4 treatment. (A) Plots show the percentage of TA cells that were CD45⁺. (B–D) CD45⁺, Mcs (CD45⁺/CD11b⁺/CD3⁻/F4/80⁻/Gr1^lo ^or-), and Mφs (CD45⁺/CD11b⁺/CD3⁻/F4/80⁺) data normalized to TA mass (milligrams). (E) Distribution of CD45⁺ cells in the TA: Mφs (pink; CD11b⁺/CD3⁻/F4/80⁺), inflammatory Mcs (black; Ly6C^Hi/Gr1^Lo), Mcs (black above gray border; Ly6C^Hi/Gr1⁻), patrolling Mcs (gray; Ly6C^Lo ^or-/Gr1⁻), neutrophils (blue; Ly6C^Lo/Gr1^Hi), T cells (gray above the blue; CD3⁺), and CD11b⁻/CD3⁻ (white). (F) Gating of myeloid (CD45⁺/CD11b⁺/CD3⁻/F4/80⁻) cells on day 6. Plots show diminishing inflammatory Mcs (Ly6C^Hi/Gr1^Lo) with PA4 treatment. (G) Inflammatory Mcs (CD45⁺/CD11b⁺/CD3⁻/F4/80⁻/Gr1^Lo/Ly6C^Hi) in TA normalized by mass (milligrams). Data are means ± SEM, n = 5–10. *P < 0.05; **P < 0.01; ***P < 0.001. Asterisks above columns indicate significance vs. contralateral. Cont, contralateral; Isch, ischemic.